Media

ALTIMMUNE RECEIVES BARDA CONTRACT OF UP TO $120.2 MILLION TO FUND CLINICAL DEVELOPMENT OF FIRST-IN-CLASS ANTHRAX VACCINE CANDIDATE NASOSHIELD

Onxeo Reports First-Half 2016 Business Update and Consolidated Financials

Cash position and revenue for the 1st semester of 2016

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

Nexstim Plc announces long-term financing arrangements in the form of a joint deal with Bracknor and Sitra

GenSight Biologics announces successful IPO on Euronext Paris

Interim report H1 2016: Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US.